(2R,5S) -Ritlecitinib

(2R,5S) -Ritlecitinib (2R,5S) -PF-06651600) is a JAK3 inhibitor (IC50=144.8 nM) [1][2].

Product Specifications

CAS Number

[1792180-79-0]

Product Name Alternative

(2R,5S) -PF-06651600

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/2r-5s-ritlecitinib.html

Concentration

10mM

Purity

99.77

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@@H]1CC[C@@H](CN1C(C=C)=O)NC2=C3C=CNC3=NC=N2

Molecular Formula

C15H19N5O

Molecular Weight

285.35

References & Citations

[1]Matthew Frank, et al. Pyrrolo[2,3-d]pyrimidinyl-, pyrrolo[2,3-b]pyrazinyl-and pyrrolo[2,3-d]pyridinylacrylamides as JAK inhibitor and their preparation. World Intellectual Property Organization, WO2015083028 A1 2015-06-11.|[2]Thorarensen A, et al. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1- ((2 S, 5 R) -5- ((7 H-Pyrrolo [2, 3-d] pyrimidin-4-yl) amino) -2-methylpiperidin-1-yl) prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. Journal of medicinal chemistry, 2017, 60 (5) : 1971-1993.